AB 2095,
as amended, Travis Allen. begin deleteEconomic development. end deletebegin insertMedi-Cal: prescriptions.end insert
Existing law establishes the Medi-Cal program, administered by the State Department of Health Care Services, under which health care services are provided to qualified, low-income persons. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions.
end insertbegin insertThis bill would require the Legislative Analyst’s Office to conduct or cause to be conducted a study comparing the purchase or administration of brand name prescription medications through the Medi-Cal program to the purchase or administration of biosimilars through the Medi-Cal program, as specified. The bill would require the study to cover the 2013-14 and 2014-15 fiscal years and to be completed on or before January 1, 2018.
end insertExisting law creates various state agencies and authorizes certain of those agencies to regulate the operations of businesses. Existing law, until January 1, 2018, authorizes cities and counties to establish capital investment incentive programs to attract large manufacturing facilities to invest in their communities and to encourage industries, such as high technology, aerospace, automotive, biotechnology, software, and environmental sources and others, to locate and invest in those facilities in California.
end deleteThis bill would express the intent of the Legislature to enact legislation that would enhance and advance opportunities for California’s biotechnology industry.
end deleteVote: majority.
Appropriation: no.
Fiscal committee: begin deleteno end deletebegin insertyesend insert.
State-mandated local program: no.
The people of the State of California do enact as follows:
The Legislative Analyst’s Office shall conduct or
2cause to be conducted a study comparing the purchase or
3administration of brand name prescription medications through
4the Medi-Cal program to the purchase or administration of
5biosimilars through the Medi-Cal program. The study shall cover
6the 2013-14 and 2014-15 fiscal years and shall be completed on
7or before January 1, 2018. The study shall breakdown the
8information by the age, ethnicity, and gender of the Medi-Cal
9recipients who purchase those medications or to whom the
10medications are administered.
It is the intent of the Legislature to enact
12legislation that would enhance and expand opportunities for
13California’s biotechnology industry.
O
98